This Article Full Text Full Text (PDF) All Versions of this Article: 116/23/2687    most recent CIRCULATIONAHA.107.723270v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Solomon, S. D. Search for Related Content PubMed PubMed Citation Articles by Solomon, S. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information End of Life Issues Kidney Diseases Related Collections Chronic ischemic heart disease

(Circulation. 2007;116:2687-2693.)
© 2007 American Heart Association, Inc.

Coronary Heart Disease

Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease

Scott D. Solomon, MD^*; Julie Lin, MD, MPH^*; Caren G. Solomon, MD, MPH; Kathleen A. Jablonski, PhD; Madeline Murguia Rice, PhD; Michael Steffes, MD; Michael Domanski, MD; Judith Hsia, MD; Bernard J. Gersh, MBChB, DPhil; J. Malcolm O. Arnold, MD; Jean Rouleau, MD; Eugene Braunwald, MD; Marc A. Pfeffer, MD, PhD, for the Prevention of Events With ACE Inhibition (PEACE) Investigators

From the Divisions of Cardiovascular Medicine, Renal Medicine, and General Medicine, Brigham and Women’s Hospital (S.D.S., J.L., C.G.S., E.B., M.A.P.), Boston, Mass; George Washington University Biostatistics Center (K.A.J., M.M.R., J.H.), Rockville, Md; University of Minnesota Medical Center (M.S.), Minneapolis, Minn; National Heart, Lung, and Blood Institute (M.D.), Bethesda, Md; Mayo Clinic College of Medicine (B.J.G.), Rochester, Minn; London Health Sciences Centre, (J.M.O.A.), London, Ontario, Canada; and University of Montreal (J.R.), Montreal, Quebec, Canada.

Correspondence to Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail ssolomon{at}rics.bwh.harvard.edu

Received June 22, 2007; accepted September 27, 2007.

Background— Patients with chronic kidney disease are at increased risk for cardiovascular morbidity and mortality. We assessed the association between albuminuria and the risks for death and cardiovascular events among patients with stable coronary disease.

Methods and Results— We studied patients enrolled in the Prevention of Events with an ACE inhibitor (PEACE) trial, in which patients with chronic stable coronary disease and preserved systolic function were randomized to trandolapril or placebo and followed up for a median of 4.8 years. The urinary albumin to creatinine ratio (ACR) assessed in a core laboratory in 2977 patients at baseline and in 1339 patients at follow-up (mean 34 months) was related to estimated glomerular filtration rate and outcomes. The majority of patients (73%) had a baseline ACR within the normal range (<17 µg/mg for men and <25 µg/mg for women). Independent of the estimated glomerular filtration rate and other baseline covariates, a higher ACR, even within the normal range, was associated with increased risks for all-cause mortality (P<0.001) and cardiovascular death (P=0.01). The effect of trandolapril therapy on outcomes was not modified significantly by the level of albuminuria. Nevertheless, trandolapril therapy was associated with a significantly lower mean follow-up ACR (12.5 versus 14.6 µg/mg, P=0.0002), after adjustment for baseline ACR, time between collections, and other covariates. An increase in ACR over time was associated with increased risk of cardiovascular death (hazard ratio per log ACR 1.74, 95% CI 1.08 to 2.82).

Conclusions— Albuminuria, even in low levels within the normal range, is an independent predictor of cardiovascular and all-cause mortality.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				I. S. Anand, K. Bishu, T. S. Rector, A. Ishani, M. A. Kuskowski, and J. N. Cohn Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure Circulation, October 20, 2009; 120(16): 1577 - 1584. [Abstract] [Full Text] [PDF]

				P.-H. Groop, M. C. Thomas, J. L. Moran, J. Waden, L. M. Thorn, V.-P. Makinen, M. Rosengard-Barlund, M. Saraheimo, K. Hietala, O. Heikkila, et al. The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes Diabetes, July 1, 2009; 58(7): 1651 - 1658. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]

				J. Lin, R. J. Glynn, N. Rifai, J. E. Manson, P. M. Ridker, D. M. Nathan, and D. A. Schaumberg Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial Diabetes Care, December 1, 2008; 31(12): 2338 - 2343. [Abstract] [Full Text] [PDF]

				J. Danziger Importance of Low-Grade Albuminuria Mayo Clin. Proc., July 1, 2008; 83(7): 806 - 812. [Abstract] [Full Text] [PDF]